Filing Flows › Nektar Therapeutics (NKTR) › R&D spending
Nektar Therapeutics (NKTR) R&D spending by quarter
Nektar Therapeutics' R&D spending was $39.1M in Q2 2026 (second quarter 2026), +10% from Q1 2026. Over the last 6 quarters it ranged from $27.3M (Q3 2025) to $39.1M (Q2 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $39.1M | +10% | +31% |
| Q1 2026 | $35.7M | +20% | +17% |
| Q4 2025 | $29.7M | +9% | — |
| Q3 2025 | $27.3M | -9% | — |
| Q2 2025 | $29.9M | -2% | — |
| Q1 2025 | $30.5M | — | — |
Q2 2026 at a glance
Nektar Therapeutics, Q2 2026: revenue $10.1M (-9% year over year), operating margin -417.9%, net loss $40.6M, operating cash flow −$75.8M. The chart follows the revenue to costs, profit and cash.
Questions
What is Nektar Therapeutics' R&D spending?
Nektar Therapeutics' R&D spending was $39.1M in Q2 2026 (second quarter 2026), +10% from Q1 2026.
How has Nektar Therapeutics' R&D spending changed?
Over the last 6 quarters it ranged from $27.3M (Q3 2025) to $39.1M (Q2 2026).